Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator''s choice in relapsed or refractory mantle cell lymphoma - Université de Lille Accéder directement au contenu
Article Dans Une Revue British Journal of Haematology Année : 2018

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator''s choice in relapsed or refractory mantle cell lymphoma

Simon Rule

Résumé

In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.
Fichier principal
Vignette du fichier
bjh.15025.pdf (314.34 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03196163 , version 1 (12-04-2021)

Licence

Identifiants

Citer

Luca Arcaini, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, et al.. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator''s choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology, 2018, British journal of haematology, 180, pp.224-235. ⟨10.1111/bjh.15025⟩. ⟨hal-03196163⟩

Collections

UNIV-LILLE
15 Consultations
38 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More